Engineered Immune Cell Therapies for Enhancing Immune Function in Nutrient-Deprived Tumor Microenvironments

Background

The field of cancer immunotherapy, particularly adoptive cell therapies such as CAR-T cell therapy, has shown significant promise in treating various malignancies by harnessing the body’s own immune system to target and destroy cancer cells. However, the effectiveness of these therapies is often compromised by the unique metabolic challenges present within the tumor microenvironment. Tumors are typically characterized by poor vascularization, leading to regions with low oxygen (hypoxia), high concentrations of metabolic byproducts like lactate, and a scarcity of essential nutrients such as glucose, amino acids, and cofactors. These harsh conditions can severely limit the proliferation, survival, and cytotoxic function of immune cells, ultimately reducing the efficacy of immunotherapies and contributing to tumor persistence or relapse.

Current approaches to overcoming these metabolic barriers have focused on systemic administration of metabolic supplements or co-administering immune checkpoint inhibitors, but these strategies have notable limitations. Systemic supplementation often fails to achieve sufficient concentrations of nutrients within the tumor microenvironment due to poor perfusion and can lead to off-target effects or toxicity. Meanwhile, checkpoint inhibitors can enhance immune cell activation but do not address the underlying issue of nutrient deprivation that impairs immune cell metabolism and function. Moreover, immune cells engineered for enhanced tumor targeting (such as CAR-T cells) remain vulnerable to the metabolic constraints imposed by the tumor milieu, resulting in suboptimal persistence and anti-tumor activity. Consequently, there is a critical need for solutions that directly address the metabolic limitations faced by immune cells within tumors to fully realize the potential of cancer immunotherapy.

Technology

This technology enhances the effectiveness of immune cell therapies, particularly CAR-T cell therapy, by genetically engineering immune cells to express metabolic enzymes such as asparaginase. These enzymes catalyze the conversion of asparagine to aspartate, thereby increasing the availability of critical substrates required for protein and nucleotide synthesis—processes that are often impaired in the nutrient-poor, hypoxic, and high-lactate environments typical of solid tumors. The metabolic enzymes can be introduced into immune cells using viral or non-viral vectors and can be targeted to specific intracellular compartments, such as the mitochondria or cytosol, to optimize their metabolic impact. This modification enables the engineered immune cells to sustain proliferation, survival, and cytotoxic activity even under severe metabolic stress, and the approach can be combined with other immunotherapies, such as checkpoint inhibitors, to further boost anti-tumor efficacy.

What differentiates this technology is its strategic focus on overcoming the metabolic barriers that limit immune cell function within the tumor microenvironment. Unlike conventional CAR-T therapies, which may falter in solid tumors due to nutrient deprivation and metabolic suppression, this approach directly addresses those constraints by equipping immune cells with the means to generate essential metabolites internally. By increasing the intracellular levels of aspartate or alanine, the engineered cells maintain their biosynthetic and energy needs, supporting robust immune responses where other therapies may fail. The flexibility to use enzymes from various sources, target different cellular compartments, and combine with a wide range of existing cancer treatments further distinguishes this solution, making it a versatile and powerful platform for expanding the reach and effectiveness of cell-based immunotherapies across diverse and challenging cancer types.

Benefits

• Enhances immune cell survival and proliferation in nutrient-poor, metabolically hostile tumor microenvironments.
• Increases availability of key metabolites (e.g., aspartate) necessary for protein and nucleotide synthesis in immune cells.
• Improves the cytotoxic activity and persistence of CAR-T and other engineered immune cells against tumors.
• Enables immune cells to function effectively under low oxygen, high lactate, and limited nutrient conditions typical of solid tumors.
• Allows targeted intracellular localization of metabolic enzymes to optimize immune cell metabolic flux.
• Can be combined with other immunotherapies, such as checkpoint inhibitors, to enhance overall anti-tumor efficacy.
• Applicable to a broad range of cancers, including solid tumors and hematological malignancies.
• Utilizes established genetic engineering methods for ex vivo modification and clinical administration of immune cells.

Applications

• Enhanced CAR-T therapy for solid tumors
• Combination immunotherapy with checkpoint inhibitors
• Engineered T cell therapy for hematological cancers

Additional info

These engineered CAR-T cells express metabolic enzymes like asparaginase to thrive in nutrient-restricted tumor microenvironments. By catalyzing asparagine-to-aspartate conversion, they maintain protein and nucleotide synthesis necessary for proliferation and cytotoxicity. Utilizing viral or non-viral vectors for intracellular localization, these modifications enable sustained immune function under hypoxic and high-lactate conditions. This approach enhances therapeutic potency against various malignancies, especially when combined with checkpoint inhibitors.